Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Husser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umana P. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018;24(19):4785–97.

Article  CAS  PubMed  Google Scholar 

Wang C, Liu Y. Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH annual meeting. J Hematol Oncol. 2023;16(1):20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dickinson M, Viardot A, Marks R, Topp MS, Morschhauser F, Jacobs B, Tani M, Bosch F, Esteban D, Cordoba R, Kaufman D, Wu C, Humphrey K, Baumlin P, Barrett M, Qayum N, Pinto A. Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study. J Clin Oncol. 2023;41(16_suppl):7549–7549.

Article  Google Scholar 

Falchi L, Carlo-Stella C, Morschhauser F, Hutchings M, Bachy E, Cartron G, Khan C, Tani M, Martinez-Lopez J, Bartlett NL, Salar A, Brody J, Leppä S, Mulvihill E, Lundberg L, Relf J, Xie Y, Bottos A, Humphrey K, Dickinson M. Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study. J Clin Oncol. 2023;41(16_suppl):7550–7550.

Article  Google Scholar 

Bock AM, Nowakowski GS, Wang Y. Bispecific antibodies for non-Hodgkin lymphoma treatment. Curr Treat Opt Oncol. 2022;23(2):155–70.

Article  Google Scholar 

Cao Y, Marcucci EC, Budde LE. Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting. J Hematol Oncol. 2023;16(1):69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olszewski AJ, Huntington SF, Ollila T, Pelcovits A, McMahon JB, Yakirevich I, Sturtevant A, Chorzalska A, Morgan J, Dubielecka P. A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL). J Clin Oncol. 2023;41(16_suppl):TPS7588–TPS7588.

Article  Google Scholar 

Westin J, Olszewski AJ, Fogliatto L, Kim WS, Shin H-J, Jeon Y-W, Norasetthada L, Pavlovsky A, Rego E, Wu H, Yin S, Batlevi CL, Pham S, Penuel EM, Jing J, Wei MC, Budde LE. SUNMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. J Clin Oncol. 2023;41(16_suppl):TPS7586–TPS7586.

Article  Google Scholar 

Lugtenburg P, Mous R, Clausen MR, Chamuleau MED, Johnson P, Linton K, Rule S, Oliveri RS, DeMarco D, Hiemstra IH, Chen G, Azaryan A, Gupta M, Ahmadi T, Hutchings M. First-in-human, phase 1/2 trial to assess the safety and clinical activity of subcutaneous GEN3013 (DuoBody®-CD3×CD20) in B-cell non-Hodgkin lymphomas. Blood. 2019;134(Supplement_1):758–758.

Article  Google Scholar 

Karimi Y, Ghesquieres H, Jurczak W, Cheah C, Clausen M, Lugtenburg P, Cunningham D, Do YR, Lewis DJ, Gasiorowski R, Kim TM, van der Poel M, Poon MLM, Feldman TA, Linton KM, Sureda A, Hutchings M, Cota Stirner M, Sacchi M, Thieblemont C. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: updated results from the pivotal EPCORE NHL-1 trial. J Clin Oncol. 2023;41(16_suppl):7525–7525.

Article  Google Scholar 

Falchi L, Clausen M, Offner F, de Vos S, Brody J, Linton KM, Snauwaert S, Cordoba R, Wu J, Bykhovski I, Wang L, Rana A, Belada D. Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: updated EPCORE NHL-2 data. J Clin Oncol. 2023;41(16_suppl):7519–7519.

Article  Google Scholar 

Merryman R, Belada D, Sureda A, Leppä S, Vermaat JSP, Holte H, Hutchings M, Lugtenburg P, de Vos S, Abrisqueta P, Nijland M, Christensen JH, Wahlin BE, Linton KM, Wang L, Abbas A, Rana A, Quadri S, Falchi L. Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. J Clin Oncol. 2023;41(16_suppl):7506–7506.

Article  Google Scholar 

Sehn LH, Chamuleau M, Lenz G, Clausen M, Haioun C, Izutsu K, Davies AJJ, Zhu J, Oki T, Szafer-Glusman E, Conlon R, Chiou H, Ipe D, Elliott B, Wu J, Salles GA. Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2. J Clin Oncol. 2023;41(16_suppl):TPS7592–TPS7592.

Article  Google Scholar